Synthetic peptide corresponding to Human LC3B (N terminal). Synthetic peptide made to the N terminal region of human LC3, isoform B protein.
Database link: Q9GZQ8
ab51520 has been shown to work on human malignant brain tumors, breast cancer, leukemia samples, and murine cells.
The product formulation changed to include 1% BSA on 17th May 2017. The following lot does not contain BSA and is still in stock GR320876. All future lots will contain 1% BSA.
Our Abpromise guarantee covers the use of ab51520 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
|IHC - Wholemount||Use at an assay dependent concentration.|
|WB||1/3000. Predicted molecular weight: 15 kDa. Detects bands of ~16 kDa (LC3-II) and ~18 kDa (LC3-I).|
Immunocytochemistry/Immunofluorescence analysis of HeLa cells labelling LC3B with ab51520.An Alexa Fluor 488-conjugated Goat to rabbit IgG was used as secondary antibody (green). Actin filaments were labeled with Alexa Fluor 568 phalloidin (red). DAPI was used to stain the cell nuclei (blue).
Flow cytometry analysis of NTERA-2 cells with ab51520 at 1/200 using Dylight-488 conjugated goat anti-rabbit IgG secondary.
Immunocytochemistry/Immunofluorescence analysis of HeLa cells using anti-LC3B antibody(red) at 0.1 ug/ml. Nuclei were counterstained with DAPI (blue).Nuclei and alpha-tubulin were counterstained with DAPI (blue) and Dylight 550 (red).
Immunocytochemistry/Immunofluorescence analysis of HeLa cells using anti-LC3B antibody(red). Nuclei were counterstained with DAPI (blue).